

PHAR-EAST

ASIA'S PHARMA & BIOTECH FESTIVAL

Pre-Conference 28 February 2018 | Main Conference 1 -2 March 2018 | Suntec Convention Centre, Singapore

Featuring in 2018

PHAR-EAST
IMMUNOTHERAPY

PHAR-EAST
VACCINES

PHAR-EAST
MARKET ACCESS

PHAR-EAST
CELL & GENE THERAPY

PHAR-EAST
PHARMA 4.0

PHAR-EAST
REGULATORY AFFAIRS

PHAR-EAST
PARTNERING & LICENSING

PHAR-EAST
BIOTECH INNOVATION

PHAR-EAST
BIOSIMILARS

ज़िन्दगी

ជីវិត

BUHAY

အသက်

人生

KEHIDUPAN

LIFE

性命

ജീവിത

생명

வாழ்க்கை

SỰ SỐNG

ជីវិត

www.terrapiinn.com/phareast

Created by

SPARK SOMETHING
TERRAPINN

Our story

From humble beginnings as BioMedical Asia in 2008, BioPharma Asia served over 22,000 attendees over its first 10 years. But fast forward 10 years later and things look markedly different.

Asia is more than just a pharma sales & marketing destination, and it's more than a cheaper manufacturing hub. Now, it leads the way with pharma innovation and R&D. Home to ecosystems ripe for innovation,

including biotech hubs in Singapore, China and Korea, Asia is taking us to new frontiers in cutting-edge research and creating exciting breakthrough therapies. So we thought it was time for a change too.

Welcome to Phar-East.




Building on the success of our global life sciences portfolio, we're bringing you a greatest hits event. Across 3 days, we'll

be exploring 9 of the most exciting pharma areas in Asia: immunotherapy, vaccines, cell & gene therapy, market access, biosimilars, regulatory affairs, partnering & licensing, pharma 4.0 and biotech innovation.

It's our biggest agenda ever, showcasing the very best in Asian pharma excellence. It's where big pharma and biotech, regulators and payers, solution providers and technology leaders all come together

to build new relationships, cement existing partnerships and chart the path forward in Asia's life sciences industry.

Join us for this new and exciting journey.



BOOK YOUR TICKETS NOW

To register:

Online: www.terrapinn.com/phareast

Call **Sunny** on 65 6322 2340 Email: sunny.wilson@terrapinn.com

For speaking involvement, please contact
Emily Chong at emily.chong@terrapinn.com
or +65 6322 2339.



Global advances.

Local perspectives.



Innovation. Access. Commercialisation.

BOOK YOUR TICKETS NOW

To register:

Online: www.terrapiinn.com/phareast

Call **Sunny** on 65 6322 2340

Email: sunny.wilson@terrapiinn.com

2018 Speakers

ASIAN PHARMA



Forrest Hu
General Manager,
International Business
3SBio, China



Tabassum Khan
Chairman
AJ Pharma, Malaysia



Mike Zhang
CEO
**Liaoning Chengda
Biotechnology, China**



Lalit Baregama
General Manager-
Business Development
International SBU
**Cadila
Pharmaceuticals,
India**



Tony Liu
CEO & CFO
**Cellular
Biomedicine, China**



Koichi Miyazaki
Senior Director,
Regulatory Affairs,
Asia Development
Department
Daiichi Sankyo, Japan



Uday Saxena
President &
CEO, **Reddy US
Therapeutics**, Former
CSO, **Dr Reddy's
Laboratories, India**



Stewart Geary
Senior Vice President,
Chief Medical Officer,
Director, Corporate
Medical Affairs
Headquarters
Eisai, Japan



Joe Zhou
CEO
**Genor Biopharma,
China**



GS Reddy
Chief General Manager
**Indian
Immunologicals,
India**



Junjian Liu
Vice President, Head of
Biologics Discovery
Innovent, China



Dinesh Kundu
Biologics Strategy and
Project Manager
**Intas
Pharmaceutical,
India**



Bobby George
VP & Head of Regulatory
Affairs
**Reliance Life
Sciences, India**



Prathibha Shetty
Head, Regenerative
Medicine Group
**Reliance
Lifesciences, India**



**Wannarak
Siraarparsate**
Business Manager
**Siam Bioscience,
Thailand**



Anushree Agarwal
Senior Manager,
Launch Readiness and
Excellence, Portfolio
Management, Emerging
Markets
Takeda, Singapore



Do Tuan Dat
General Director
**Vaccine and
Biological
Production
(Vabiotech), Vietnam**



Kaustubh Berde
Vice President,
Emerging Markets
Wockhardt, India



Joyce YanWei Liu
Senior Director,
Regulatory Affairs
**JW Therapeutics,
China**



Shuyuan Yao
Vice President,
Operations
**JW Therapeutics,
China**



Gopal Rao
Senior Manager, Global
Business Development
and Licensing
Lupin, India



Marc Voigt
CEO
Immutep, Australia



Yuliana Indriati
President Director
**PT Kalbe Genexine
Biologics, Indonesia**



H.Fai Poon
Chief Scientific Officer
**Zhejiang Hisun
Pharmaceuticals,
China**



Solomon Alva
Antibody Purification
Group Head, Senior
Scientific Manager
**Biocon Research,
India**



John Zeng
Executive Vice
President
**Shanghai Zerun
Biotechnology, China**



Hardy Chan
Chairman & President
**Allianz
Pharmascience,
Taiwan**



**Himanshu
Brahmbhatt**
Joint-CEO & Director
**EnGeneIC, Cancer
Therapeutics,
Australia**

JAPAC BIOTECH



John Connolly
Chief Scientific Officer
**Tessa Therapeutics,
Singapore**



Sean Lin Huang
CEO
**Amwise Diagnostic,
Singapore**



**Skye Hung-Chun,
Cheng**
Chief Scientist
**Amwise Diagnostic,
Singapore**



Bandana Sharan
President & Director,
Research
APAC Biotech, India



Robin Low
Founder & CEO
Areteon, Singapore



Karen Tseng
CEO
**BioPreventive
Medicine, Taiwan**



Ke Wu
CEO
BravoVax, China



Ivor Lim
Co-Founder and Chief
Medical Officer
**CellResearch Corp,
Singapore**



Frank Jiang
CEO
**CStone Pharma,
China**



Erick Co
Chief Scientific Officer
**Formosa
Pharmaceuticals,
Taiwan**



Kenji Kakuta
President & CEO
**iHeart Japan
Corporation, Japan**



Sujay Singh
President & CEO
**Imgenex India Pvt.
Ltd., India**



Lei Xiao
CSO and Chairman
**Innovative Cellular
Therapeutics, China**



Gloria Wang
Executive Director,
Clinical Development
**Just
Biotherapeutics,
China**



Jerry Huang
Business Development
Associate Director
**Lin Bioscience,
Taiwan**



Antonio Bertoletti
Co-Founder
LionTCR, Singapore



Victor Li
CEO
LionTCR, Singapore



James Garner
CEO
**Kazia Therapeutics,
Australia**



Tim Collard
CEO
**Pacific Gene Tech,
China**



Cindy Tsang
Director of Business
Development
**Pacific Gene Tech,
China**



Jin-San Yoo
CEO
**PharmAbcine,
South Korea**



Paul Howley
CEO, CSO and Co-
Founder
Sementis, Australia




B N Manohar
Managing Director
Stempeutics, India



Han Chong Toh
Chief Medical Officer
**Tessa Therapeutics,
Singapore**

View full speaker line
up on our website:
[www.terrapinn.com/
phareast](http://www.terrapinn.com/phareast)



View full speaker line up on our website:
www.terrapinn.com/phareast

2018 Speakers

PRE-CONFERENCE



Junghee Lim
Director, Bioteam
Intervest, South Korea



Ahmad Redzuan Sidek
Chief Investment Officer
ABio, Malaysia



Kenneth Noonan
CEO
Lightstone, Singapore



Bien Kiat Tan
Managing Director
Titan Capital, Singapore



Sean Hsiao
Vice President
Top Taiwan Venture Capital Group, Taiwan



Hui Hsing Ma
Senior Deal Advisor, SEA
TVM Capital Healthcare, Singapore



Carolyn Ng
Vice President
Vertex Ventures, a member of Temasek Holdings, Singapore



John Zhu
Partner
Wuxi Venture, China




Aditya Puri
Investment Partner
Xeraya Capital Sdn Bhd, Malaysia



Jason Rushton
Investment Partner
Xeraya Capital Sdn Bhd, Malaysia



Fang Soong Chou
General Partner
C Pix Vine Capital, Singapore



Damien Lim
General Partner
BioVeda Capital, Singapore



Patrick De Silva
Chief Investment Partner
Pix Vine Capital, Singapore



Jacob Jensen
Senior Manager, Program Management, Manufacturing Sciences
Biogen, Denmark



Robert Bruno
Director, Clinical Program Development
AbbVie, Japan



James Cai
VP Global Regulatory Affairs, Access & Policy
Amgen, China



Sonika Shah
Head, Regulatory Affairs
Amgen, India




Jack Wong
Head of Regulatory Affairs
Baxter, Singapore



Shwen Gwee
Head of Digital Strategy, Global Clinical Operations
Biogen, USA



Edith Jasny
Senior Scientist
Curavec, Germany



Yan Fang Liu
Senior Director, Senior Director, Epidemiology Lead for Asia Pacific
J&J, Singapore



Christian Wards
Director of Group Healthcare
AIA, China




Malini Raj
Non-Executive Director
World Alliance of Pituitary Organisations (WAPO), Australia



I-Ning Tang
Senior Reviewer
Center of Drug Evaluation, Taiwan



Chung-lin Yang
Team Leader, Division of Health Technology Assessment
Centre of Drug Evaluation, Taiwan




Oscar Luo
Research Scientist
Australian E-Health Research Centre, CSIRO Health and Biosecurity, Australia



Ogan Gurel
Founder & CEO,
NovumWaves, South Korea




Ayan Dey
Research Scientist
International Vaccine Institute, South Korea



Levent Shih-Jen Liu
Investigator and CEO of Bioproduction Plant
Health Research Institutes, Taiwan



Tran Hien Nguyen
Director
National Institute of Hygiene and Epidemiology, Vietnam



Joseph Mocanu
Principal, Life Sciences and Digital Health
Oliver Wyman, Singapore



Woong-Yang Park
Director
Samsung Genomic Institute, South Korea



Mrunalini Jagtap
Data Management Lead
Singapore Institute for Clinical Sciences (SICS), A*STAR, Singapore



Danilo Tagle
Associate Director for Special Initiatives, National Center for Advancing Translational Sciences
National Institutes of Health, USA



Carrie Hillyard
Founder
CM Capital, Australia beside Patrick De Silva

WORKSHOP & SITE TOUR – 28 FEBRUARY 2018

9 AM – 12 PM EUROPEAN PATENT WORKSHOP

The European Patent Office will bring you hands-on practical case studies to illustrate to you all you need to know on European patents and the opportunities within.

Sponsored By:



9AM-5PM REGULATORY AFFAIRS WORKSHOP

This workshop addresses the overview of regulatory affairs in Asia. Key discussion includes- key definition of medical devices, key regulatory framework in established vs developing countries, common problems and potential solutions to regulatory challenges in industry with an optional exam and certificate provided at the end of the conference.

Jack Wong, Head of Regulatory Affairs, **Baxter, Singapore**

in collaboration with



2pm-5pm SITE TOUR

Join us for an interactive site tour and witness the discovery and/or manufacturing capabilities in Singapore's pharma industry. Last March 2017 we visited A*STAR's lab. In March 2016 we visited Baxalta Manufacturing Plant. Stay tuned for our 2018 announcement!

BOOK 3-DAY PASS NOW TO ENJOY ACCESS TO WORKSHOPS, SITE TOUR AND PREMIUM CONFERENCE:

To register:

Online: www.terrapiinn.com/phareast

Call **Sunny** on 65 6322 2340

Email: sunny.wilson@terrapiinn.com

9AM-5PM BIOTECH BOOT CAMP

So you're thinking of starting a biotech? Or maybe you are very early stage and want to understand how you can secure funding. This 1 day bootcamp for aspiring biotech entrepreneurs will give you an introduction into how you establish, build and manage a biotech.

Key areas of discussion:

- Defining innovation from an investor perspective
- Perspective of a life sciences VC: What are investors looking for in a biotech start-up
- Building an entrepreneurial management team
- Effective digital strategy in biotech start-up business
- The business plan and clinical development in bio-start up setting
- Capitalisation of your venture
- Working with the media

Confirmed speakers:

Hui Hsing Ma, Senior Deal Advisor, SEA, **TVM Capital Healthcare, Singapore**

Bien Kiat Tan, Managing Director, **Titan Capital, Singapore**

Carrie Hillyard, Founder, **CM Capital, Australia**

Aditya Puri, Investment Partner, **Xeraya Capital Sdn Bhd, Malaysia**

Hardy Chan, Chairman & President of **Allianz Pharmascience**, Co-founder and senior advisor of **ScinoPharm, Taiwan**

Shwen Gwee, Head of Digital Strategy, Global Clinical Operations, **Biogen, USA**

Himanshu Brahmhatt, Joint-CEO & Director, **EnGeneIC, Cancer Therapeutics, Australia**

View full agenda online:

<http://www.terrapiinn.com/exhibition/phar-east/agenda.stm>



The conference

	DAY 1, 1ST MARCH 2018							
08:45	Organiser’s welcome remarks							
08:50	Chair’s opening remarks							
	OPENING KEYNOTE PLENARY: FINANCING & INDUSTRIAL EXCELLENCE							
09:00	Venture capital funding for the biotech industry: A case study It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important priorities than to invest in early stage companies, the role of the VC becomes even more crucial and necessary for success. Investigate how VC helps biotech to take flight in the competitive generics and biosimilar-focused Asia market. Carolyn Ng, Vice President, Vertex Ventures, a member of Temasek Holdings, Singapore							
09:20	Fostering biotech and bio-entrepreneurship in Asia: How do we build the next biotech unicorn in Southeast Asia? Southeast Asia is extremely diverse. It is a home to near 620 million people across 11 countries, each with different languages and religions. Among the countries many are still in the developing stage where R&D is not as much a priority than providing necessity to minimise the income gap between the rich and the needy. Yet thriving biotech landscape offering innovative solutions is starting to be seen. What needs to be done to help these promising companies to fully realise their potential? How can ASEAN come together in supporting the biotech industry in the region, as well as building the next possible biotech unicorn in SEA? John Connolly, Chief Scientific Officer, Tessa Therapeutics, Singapore							
09:40	Keynote panel- The Macro View: What will it take for Asia’s biotech industry to really flourish? Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D? Joe Zhou, CEO, Genor Biopharma, China Uday Saxena, President & CEO, Reddy US Therapeutics, Former CSO, Dr Reddy’s Laboratories, India Tabassum Khan, Chairman, AJ Pharma, Malaysia Mike Zhang, CEO, Liaoning Chengda Biotechnology, China							
10:20	Speed networking							
10:35	Exhibition Visit & Networking Refreshments							
	IMMUNOTHERAPY	VACCINES	BIOSIMILARS	MARKET ACCESS	PHARMA 4.0	PARTNERING & LICENSING	BIOTECH INNOVATION	
	ADVANCED THERAPY LANDSCAPE OVERVIEW: WHERE DOES ASIA FIT?	ASIA IMMUNISATION PROGRAM	BIOSIMILARS IN ASIA	ASIA PARTNERING FRAMEWORK	PHARMA 4.0: CLINICAL TRIALS			
10:55	Chair’s opening remarks	Chair’s opening remarks	Chair’s opening remarks	Chair’s opening remarks	Chair’s opening remarks	Join us at this interactive roundtable session for an informal, one hour discussion with local pharma companies interested licensing their products. Ideal for pharma companies looking for local partners and distributors, and for distributors looking for new business opportunities.	Chair’s opening remarks	
11:00	Cancer precision medicine: From screening to drug selection and development	Role of manufacturers in clearing vaccines misconception	mAb Industry in China: Biosimilars vs. Innovative Biologics	Building the right ecosystem to support the new era of Indonesia biopharma industry	Digital trends impacting clinical trials		Investor Insights	
11:10							Biotech Showcase	
11:20	Awakening the immune system against cancer - Moving into the clinic	Building affordable and sustainable vaccines framework for neglected diseases in Asia	Invention vs innovation: How Asian pharma companies remain competitive in the biosimilar space	Case study: Strategic partnership for effective pharmaceutical development and manufacturing	The Internet of Medical Things (IoMT): Big data in electronic disease surveillance, modelling and beyond	MALAYSIA & SINGAPORE	Biotech showcase	
11:30				Case study: Practical steps to prepare for product launch in APAC and Greater China			Biotech showcase	
11:40	Global pipeline development to serve Asia population	Vaccination program in Vietnam and its health impact	Cost vs quality: What’s the best strategies for Asia	Panel discussion: To partner or to launch? Strategies for exploring Asia’s emerging markets	Big data & AI in digital rare disease patient recruitment		INDONESIA	Biotech showcase
11:50							Biotech showcase	
12:00	The next big immune checkpoint: LAG-3	ROUNDTABLE DISCUSSION SESSION						
		Table 1: Upcoming vaccines in Asia and how to prepare for it	Table 2: Sustainable vaccines strategies in global health, high-income and private sector	Table 3: Sustainable biosimilar models in Asia	Table 4: Key strategies to overcome challenges in biosimilar development and manufacturing processes	Table 5: What can we learn from CAR-T, PDL1, Cancer Vaccines successes, and what’s next in Asia?	Table 6: Working on a startup setting, from clinical development to commercialisation	
12:20		Table 7: AI& Big data in drug discovery	Table 8: IoT and blockchain in clinical studies	Table 9: Pricing & Reimbursement strategies in Asia	Table 10: Reconciling the diversified pharma regulations in Asia	Table 11: Bringing it together: Roles of Patient, Pharma, Hospital and Government in Drug Development		
13:00	Exhibition Visit & Networking Lunch							



View full agenda online: <http://www.terrapinn.com/exhibition/phar-east/agenda.stm>

The conference


	IMMUNO-ONCOLOGY	VACCINES MANUFACTURING: COST & EFFICIENCY	BIOSIMILAR REGULATION	PRICING & REIMBURSEMENT	PHARMA 4.0: DRUG DISCOVERY	PARTNERING & LICENSING	BIOTECH INNOVATION
14:10	Chair’s opening remarks	Chair’s opening remarks	Chair’s opening remarks	Chair’s opening remarks	Chair’s opening remarks	THAILAND & VIETNAM	Chair’s opening remarks
14:20	Anti-viral immunotherapy: A case study	Addressing the complexity in low cost, high volume vaccines manufacturing	Operating in countries with developing biosimilar guidelines	Value in healthcare: A payer’s perspective	Fast-tracking drug discovery with supercomputers and artificial Intelligence (AI)		Investor Insights
14:30							Biotech showcase
14:40	Dendritic cell vaccines in Asia: The first CDSCO approved Indian dendritic cell cancer immunotherapy	Challenges, innovations and opportunities in Chinese state owned vaccines company: A case study on Chengda Biotech	Could adoption of biosimilars be slowed due to government rebates on biologics?	Promoting access to healthcare in developing countries	Moving towards personalised medicine: Using big data to predict and customise treatment	CHINA	Biotech showcase
14:50							Biotech showcase
15:00	Nanocell platform for the targeted cyto-immunotherapy in cancer	A case study of Vabiotech: Challenges in vaccine development and production in Vietnam	Regulatory and quality requirements for biosimilar filing- An overview	Impact of India’s latest regulatory framework on drug development, production, pricing and reimbursement	Genome data mining and analysis for new drug discovery		Biotech showcase
15:10							Biotech showcase
15:20	Exhibition Visit & Networking Refreshments						
	COMBINATION IMMUNOTHERAPY	ASIA VACCINE INNOVATION	BIOIMILARS DEVELOPMENT	HTA& HEOR	PHARMA 4.0: MANUFACTURING & SUPPLY CHAIN	PARTNERING & LICENSING	BIOTECH INNOVATION
16:00	Building the framework of combination immuno-oncology (I-O)	Overcoming the complexities of conjugate vaccine production	Choosing the right Asian country for your biosimilar trials	Practicing HEOR activities in Asia	IoT in Pharma manufacturing: What have we learnt so far?	INDIA	Investor Insights
16:20	Using genetic information to predict the effectiveness of combination immunotherapy	Next generation universal vaccines	India’s Biosimilar clinical trials landscape: What do you need to know?	HTA in Taiwan: An update	Better decision making with big data analytics		Biotech showcase
							Biotech showcase
16:40	Expansions of trials for with Avastin refractory recurrent GBM patients and combination of Tanibirumab + anti-PD1 antibody for refractory cancer patients	Upscaling thermostable vaccines: Where are we now?	Moving from generic antibody supplier to biosimilars developers: Key insights learnt from development to biosimilars productions	Technology assessment for new oncology drug	Asset management and fleet tracking with IoT	PHILIPPINES	Biotech showcase
							Biotech showcase
							Biotech showcase
17:00	Networking Cocktail & Phar-East Industry Awards Presentation						
	DAY 2, 2ND MARCH 2018						
09:00	Organiser’s welcome remarks						
09:05	Chair’s opening remarks						
	DISRUPTION & DIGITALISATION						
09:10	Shifting paradigm of the advanced therapy landscape in Asia Recently raised to fame as the new miracle method to treat even the most stubborn cancer cases, CAR-T trials have proven to save patients who have failed all known treatment. From a pharma perspective, what methods can they adopt to produce these highly personalised, customised treatments at scale? Upon approval for commercial deployment, what else needs to be done to help patients afford the sky high cost of immunotherapy? Join this thought provoking presentation to hear from Tony Liu, CEO of CBMG and former senior executive of Alibaba and Microsoft to learn how this influential biopharma company take steps to prepare for the next miracle drug in making. Tony Liu , CEO & CFO, Cellular Biomedicine, China						
09:30	Pharma 4.0: How digitisation & disruption are creating a need for agility and entrepreneurship in pharma Digitisation is changing the way pharma interacts with payers, doctors and patients, leading pharma to seek out different skills and personality traits in employees. The challenge is selecting the right disruptor to foster a forward-thinking organisation, and identifying the suitable digital strategy whilst also complying with local regulations and continuing to invest in core R&D capabilities. Hear from big pharma on how they are moving forward and embracing the digital disruption.						
09:50	Educated guesses, lofty aspirations, hard realities Ideas are free and to be able to catch one by the wings and bring it back to ground is a wonderful feeling indeed. For doctors, the next step is to bring this good idea into the wards for the patient’s benefit. The transition of bench research to bedside application seems very straightforward at first glance, but it is not until the first steps are taken that one realises the numerous hurdles that have to be surmounted in order to achieve this. In the best interests of the patient, this translational sequence is prescriptive and tedious, and yet it pays no heed to other essentials crucial for the translational effort to be truly successful. This presentation also shares the journey of CellResearch Corporation which 13 years to see the light at the end of the tunnel. Ivor Lim , Co-Founder and Chief Medical Officer, CellResearch Corp, Singapore						
10:10	Exhibition Visit & Networking Refreshments						



View full agenda online: <http://www.terrapinn.com/exhibition/phar-east/agenda.stm>

The conference

	VACCINES	BIOSIMILARS	CELL & GENE THERAPY	REGULATORY AFFAIRS	BIOTECH INNOVATION
	DELIVERY PLATFORMS	MANUFACTURING: UPSCALING	ADVANCED THERAPY LANDSCAPE	MULTI REGIONAL CLINICAL TRIAL (MRCT)	
11:00	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks
				Overview of MRCT in Asia	
11:10	Low cost, flexible universal adjuvant & delivery system to orally deliver PGT and third party inactivated vaccines for infectious diseases	Platform tech development for biosimilar upscaling	Regenerative medicine by iPSC in Japan	ICH E17	Investor Insights
11:20				Japan	Biotech Showcase
11:30	A novel platform technology for vaccine development	Continuous processing in biosimilars development and production	What's next after CAR-T in Leukaemia treatment?	Taiwan	Biotech showcase
11:40				China	Biotech showcase
11:50	Viral vs non-viral vectors for gene therapy delivery	Use of Biocapacitance probes for optimized process control at Large-Scale Manufacturing	Cell Therapy for treating Critical Limb Ischemia – an unmet medical need	Panel: Successes and future strategies to promote cross-country drug development	Biotech showcase
12:00					Biotech showcase
12:10	Exhibition Visit & Networking Lunch				
	NEXT GENERATION VACCINES	MARKETING & POST AUTHORISATION	CELL THERAPIES: MANUFACTURING	REAL WORLD EVIDENCE (RWE)	BIOTECH INNOVATION
13:40	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks
13:45	Preventing infectious diseases with nucleic acid based vaccines	Adoption of biosimilars-issues and challenges	Coping with manufacturing variability in producing cell therapy products	Evidence Based Medicine (EBM) in Asia: Latest update	Investor Insights
13:55					Biotech showcase
14:05	Potential safety concerns for nucleic acid based vaccines	Exploration and construction of physician training in handling biosimilar drugs	Panel: Selecting the right model for GMP of cell therapy products	Panel discussion: Using Real World Evidence (RWE) to support the rational use of medicine in Asia	Biotech showcase
					Biotech showcase
14:25	Bioinformatics in reverse vaccinology (RV)	Understanding post market data and Adverse Drug Response reporting for biosimilars			Biotech showcase
					Biotech showcase
14:45	Exhibition Visit & Networking Refreshments				
	VIRUS-LIKE PARTICLE (VLP) VACCINES & ADJUVANTS	BEYOND CAR-T	REGULATORY AFFAIRS: EMERGING THERAPEUTICS	BIOTECH INNOVATION	
15:15	VLP as efficient vaccines: Case study on infectious diseases	Case study: What it takes to achieve commercial success for cell & gene therapy products	Good Pharmacovigilance Practice (GVP): What can Asia learn from the EMA?	Investor's sharing	
15:25				Biotech showcase	
15:35	Construction of VLP expression systems and purification methods	Innovative tools for risk assessment in drug development	Advanced Cell Therapy Regulatory Evaluation in China	Biotech showcase	
15:45				Biotech showcase	
15:55	Artificial VLPs as adjuvants	Combining CAR-T with checkpoint inhibitor	Pharmacovigilance practices to keep pace with severe adverse effects	Biotech showcase	
16:05				Biotech showcase	
16:15	Close of Phar East 2018				



BOOK YOUR TICKETS NOW


To register:

Online: www.terrapinn.com/phareast

Call **Sunny** on 65 6322 2340 Email: sunny.wilson@terrapinn.com

View full agenda online:

<http://www.terrapinn.com/exhibition/phar-east/agenda.stm>



Floorplan



FOR SPONSORSHIP & EXHIBITION OPPORTUNITIES

Please Contact **Pinky
Fadullon** At Pinky.
Fadullon@Terrapinn.com
Or +65 6322 2738

2018 Sponsors & Exhibitors

Platinum Sponsor



Gold sponsor



Silver Sponsor



Bronze Sponsor



Associate Sponsor



Exhibitors



Pod-Stand Exhibitors



Advertising Sponsor



2 – Day All Access Pass (SGD)

No of Attendees	Until 12th January 2018	Until 9th February 2018	After 9th February 2018
1 – 2	\$2995	\$3145	\$3295
Group rate (3 and above)	\$1650		
Package Includes	2-Day premium conference pass Exhibition Access Lunch & Refreshments Event networking app		

3 – Day All Access Pass (SGD)

No of Attendees	Until 12th January 2018	Until 9th February 2018	After 9th February 2018
1 – 2	\$3905	\$4100	\$4295
Group rate (3 and above)	\$2150		
Package Includes	2-Day premium conference pass Choice of Full-day workshops or half-day workshop & site tour 1-Day workshop and site tour Exhibition Access Lunch & Refreshments Event networking app		

Special prices for
Pharma and Academic
representatives can be
found on our website:
[www.terrapinn.com/
phareast](http://www.terrapinn.com/phareast)

TO REGISTER:

Online:

www.terrapinn.com/phareast
or Contact **Sunny** at
sunny.wilson@terrapinn.com or
+65 6322 2340